ArticleEndocrine connections2025
Is evaluation of cortisol after dexamethasone suppression test enough? Analysis of steroid profile after dexamethasone suppression test using tandem mass spectrometry.
Article in Endocrine connections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The overnight dexamethasone suppression test (DST) is recommended for the initial testing of Cushing's syndrome. Simultaneous measurement of dexamethasone and cortisol is recommended. This study aimed to determine the cutoff value for dexamethasone measured in DST analyzed via liquid chromatography tandem mass spectrometry (2D-LC-MS/MS) and to assess whether analysis of adrenal steroids other than cortisol may improve diagnostic accuracy. Methods: A prospective study was conducted including patients with adrenal incidentalomas (n = 55), pituitary incidentalomas and symptoms of Cushing's disease (n = 18), and healthy controls (n = 100) undergoing DST. Plasma levels of ten steroids and dexamethasone were determined via 2D-LC-MS/MS, while cortisol levels were also determined via a chemiluminescence immunoassay. Results: The lower 2.5th percentile of plasma dexamethasone in the control group (cortisol level <50 nmol/L) was 3.48 nmol/L, which was set as the cutoff. In the subgroup of patients with adrenal incidentalomas, regardless of the results of DST, subjects exhibited identical changes in the basal adrenal steroid profile: increased 11-deoxycortisol and decreased DHEA and DHEAS levels. After 1 mg dexamethasone administration, cortisol and cortisone levels increased, while decreased androstenedione and 17-OHP levels were detected. Statistically significant changes were found in the subgroup of patients with pituitary incidentalomas: increased levels of 11-deoxycortisol, plasma cortisol, cortisone, and androstenedione were observed only in those with serum cortisol levels >50 nmol/L. Based on the ROC curves, none of the steroid hormones exhibited higher specificity than cortisol. Conclusion: Simultaneous measurement of cortisol and dexamethasone increases DST specificity. The cutoff value for dexamethasone was set at 3.48 nmol/L. None of the adrenal steroids in the DST demonstrated increased specificity; thus, a cortisol concentration <50 nmol/L remains the gold standard for ruling out Cushing's syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.